Moslosooflavone promotes diabetic wound healing via TrkB/PI3K-Akt signaling and macrophage polarization: in vitro and in vivo validation

Diabetic foot ulcers (DFUs) represent a severe and refractory diabetic complication characterized by persistent inflammatory activation, disordered macrophage phenotypic transformation, and impaired neurotrophic signaling. Although moslosooflavone (MOS) has been verified to possess anti-inflammatory and pro-healing bioactivities in multiple disease models, its underlying multi-target regulatory mechanisms in DFU wound repair remain poorly elucidated. Two public transcriptomic datasets (GSE134431, GSE199939) were integrated through weighted gene co-expression network analysis (WGCNA), protein–protein interaction(PPI) networks, and consensus machine learning (XGBoost (XGB), random forest (RF), LASSO regression, Boruta feature selection) to screen and validate core DFU-related targets. Potential MOS targets were predicted using SwissTargetPrediction, SEA, and TargetNet databases. Binding modes and stability were evaluated by molecular docking and 100-ns molecular dynamics (MD) simulations. Immune cell infiltration was quantified using CIBERSORT. In vitro, high-glucose-stimulated RAW264.7 macrophages were used to assess cell viability, cytokine secretion, phenotypic transformation, and pathway activation using CCK-8, ELISA, flow cytometry, RT-qPCR, and Western blotting. TrkB (K252a) and PI3K (LY294002) inhibitors were employed to confirm pathway dependency. In vivo, a streptozotocin-induced diabetic mouse full-thickness wound model received topical MOS-loaded Carbopol hydrogel. A five-gene diagnostic signature consisting of CYP1A1, MAOB, NTRK2, ESR2, and KIT exhibited high efficacy in distinguishing DFUs from normal skin tissues. Among these, CYP1A1, MAOB, and NTRK2 were prioritized as candidate MOS targets, displaying stable binding (-5.05 to -6.62 kcal/mol), sustained hydrogen bonds, RMSD < 0.5 nm, and favorable MM/PBSA free energies. These targets were functionally linked to M0/M2 macrophage homeostasis. In high-glucose-stimulated macrophages, MOS improved cell viability, suppressed pro-inflammatory cytokines, and promoted M2 polarization. Pharmacological blockade of TrkB and PI3K largely abrogated these protective effects, supporting an important role for the TrkB/PI3K-Akt axis in the observed effects of MOS. Topical MOS hydrogel dose-dependently accelerated diabetic wound closure, accompanied by increased infiltration of CD206 + M2 macrophages and elevated phospho-TrkB in F4/80 + wound macrophages. MOS facilitates diabetic wound repair via a dual regulatory mechanism. Specifically, MOS alleviates pathological oxidative damage and activates the TrkB/PI3K-Akt pro-healing signaling cascade.This synergistic dual regulation restores neurotrophic signaling homeostasis, resolves wound inflammatory microenvironment imbalance, and drives macrophage transformation into a reparative M2 phenotype, ultimately ameliorating DFU pathological progression and accelerating diabetic wound regeneration.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-20
DOI
https://doi.org/10.1038/s41598-026-69638-5
Primary Topic
Wound Healing and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Moslosooflavone promotes diabetic wound healing via TrkB/PI3K-Akt signaling and macrophage polarization: in vitro and in vivo validation

Renying He, Aijun Chen, Sihong Xue, Yanlin Yu et al.
3 links
Scientific Reports
Wound Healing and Treatments
article

Moslosooflavone promotes diabetic wound healing via TrkB/PI3K-Akt signaling and macrophage polarization: in vitro and in vivo validation

Renying He, Aijun Chen, Sihong Xue, Yanlin Yu, Peiyu Wu
article en

Abstract

Diabetic foot ulcers (DFUs) represent a severe and refractory diabetic complication characterized by persistent inflammatory activation, disordered macrophage phenotypic transformation, and impaired neurotrophic signaling. Although moslosooflavone (MOS) has been verified to possess anti-inflammatory and pro-healing bioactivities in multiple disease models, its underlying multi-target regulatory mechanisms in DFU wound repair remain poorly elucidated. Two public transcriptomic datasets (GSE134431, GSE199939) were integrated through weighted gene co-expression network analysis (WGCNA), protein–protein interaction(PPI) networks, and consensus machine learning (XGBoost (XGB), random forest (RF), LASSO regression, Boruta feature selection) to screen and validate core DFU-related targets. Potential MOS targets were predicted using SwissTargetPrediction, SEA, and TargetNet databases. Binding modes and stability were evaluated by molecular docking and 100-ns molecular dynamics (MD) simulations. Immune cell infiltration was quantified using CIBERSORT. In vitro, high-glucose-stimulated RAW264.7 macrophages were used to assess cell viability, cytokine secretion, phenotypic transformation, and pathway activation using CCK-8, ELISA, flow cytometry, RT-qPCR, and Western blotting. TrkB (K252a) and PI3K (LY294002) inhibitors were employed to confirm pathway dependency. In vivo, a streptozotocin-induced diabetic mouse full-thickness wound model received topical MOS-loaded Carbopol hydrogel. A five-gene diagnostic signature consisting of CYP1A1, MAOB, NTRK2, ESR2, and KIT exhibited high efficacy in distinguishing DFUs from normal skin tissues. Among these, CYP1A1, MAOB, and NTRK2 were prioritized as candidate MOS targets, displaying stable binding (-5.05 to -6.62 kcal/mol), sustained hydrogen bonds, RMSD < 0.5 nm, and favorable MM/PBSA free energies. These targets were functionally linked to M0/M2 macrophage homeostasis. In high-glucose-stimulated macrophages, MOS improved cell viability, suppressed pro-inflammatory cytokines, and promoted M2 polarization. Pharmacological blockade of TrkB and PI3K largely abrogated these protective effects, supporting an important role for the TrkB/PI3K-Akt axis in the observed effects of MOS. Topical MOS hydrogel dose-dependently accelerated diabetic wound closure, accompanied by increased infiltration of CD206 + M2 macrophages and elevated phospho-TrkB in F4/80 + wound macrophages. MOS facilitates diabetic wound repair via a dual regulatory mechanism. Specifically, MOS alleviates pathological oxidative damage and activates the TrkB/PI3K-Akt pro-healing signaling cascade.This synergistic dual regulation restores neurotrophic signaling homeostasis, resolves wound inflammatory microenvironment imbalance, and drives macrophage transformation into a reparative M2 phenotype, ultimately ameliorating DFU pathological progression and accelerating diabetic wound regeneration.

Scientific ReportsVol. 16(1)
Army Medical University (CN), Dalian Medical University (CN), Second Affiliated Hospital of Chongqing Medical University (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Chongqing Emergency Medical Center (CN), Chongqing Medical University (CN)
Natural Science Foundation of Chongqing
Good health and well-being
Wound Healing and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon